Myelodysplastic syndromes (MDS), clonal hematopoietic stem-cell disorders mainly affecting older adult patients, show ineffective hematopoiesis in one or more of the lineages of the bone marrow. Most MDS are characterized by anemia, and a number of cases progresses to acute myeloid leukemia (AML). Indeed, the molecular mechanisms underlying the MDS evolution to AML are still unclear, even though the nuclear signaling elicited by PI-PLCβ1 has been demonstrated to play an important role in the control of the balance between cell cycle progression and apoptosis in MDS cells. Here we review both the role of epigenetic therapy on PI-PLCβ1 promoter and the changes in PI-PLCβ1 expression in MDS patients treated for anemia.
Follo MY, Marmiroli S, Faenza I, Fiume R, Ramazzotti G, Martelli AM, et al. (2013). Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS. ADVANCES IN BIOLOGICAL REGULATION, 53(1), 2-7 [10.1016/j.jbior.2012.09.009].
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS
FOLLO, MATILDE YUNG;FAENZA, IRENE;FIUME, ROBERTA;RAMAZZOTTI, GIULIA;MARTELLI, ALBERTO MARIA;FINELLI, CARLO;MANZOLI, FRANCESCO ANTONIO;COCCO, LUCIO ILDEBRANDO
2013
Abstract
Myelodysplastic syndromes (MDS), clonal hematopoietic stem-cell disorders mainly affecting older adult patients, show ineffective hematopoiesis in one or more of the lineages of the bone marrow. Most MDS are characterized by anemia, and a number of cases progresses to acute myeloid leukemia (AML). Indeed, the molecular mechanisms underlying the MDS evolution to AML are still unclear, even though the nuclear signaling elicited by PI-PLCβ1 has been demonstrated to play an important role in the control of the balance between cell cycle progression and apoptosis in MDS cells. Here we review both the role of epigenetic therapy on PI-PLCβ1 promoter and the changes in PI-PLCβ1 expression in MDS patients treated for anemia.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
